6 results on '"Wumkes, M. L."'
Number of results to display per page
Search Results
2. Gastro-intestinale oncologie
- Author
-
van den Boogaard, D. J. M., Mandemaker, F., Rozema, T., Wumkes, M. L., van Spil, J.A., editor, van Muilekom, H.A.M., editor, Folsche, M., editor, and Schreuder-Cats, H.A., editor
- Published
- 2021
- Full Text
- View/download PDF
3. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3):study protocol for a multicenter randomized controlled trial
- Author
-
van Dam, J. L., Verkolf, E. M.M., Dekker, E. N., Bonsing, B. A., Bratlie, S. O., Brosens, L. A.A., Busch, O. R., van Driel, L. M.J.W., van Eijck, C. H.J., Feshtali, S., Ghorbani, P., de Groot, D. J.A., de Groot, J. W.B., Haberkorn, B. C.M., de Hingh, I. H., van der Holt, B., Karsten, T. M., van der Kolk, M. B., Labori, K. J., Liem, M. S.L., Loosveld, O. J.L., Molenaar, I. Q., Polée, M. B., van Santvoort, H. C., de Vos-Geelen, J., Wumkes, M. L., van Tienhoven, G., Homs, M. Y.V., Besselink, M. G., Wilmink, J. W., Groot Koerkamp, B., van Dam, J. L., Verkolf, E. M.M., Dekker, E. N., Bonsing, B. A., Bratlie, S. O., Brosens, L. A.A., Busch, O. R., van Driel, L. M.J.W., van Eijck, C. H.J., Feshtali, S., Ghorbani, P., de Groot, D. J.A., de Groot, J. W.B., Haberkorn, B. C.M., de Hingh, I. H., van der Holt, B., Karsten, T. M., van der Kolk, M. B., Labori, K. J., Liem, M. S.L., Loosveld, O. J.L., Molenaar, I. Q., Polée, M. B., van Santvoort, H. C., de Vos-Geelen, J., Wumkes, M. L., van Tienhoven, G., Homs, M. Y.V., Besselink, M. G., Wilmink, J. W., and Groot Koerkamp, B.
- Abstract
BACKGROUND: Surgical resection followed by adjuvant mFOLFIRINOX (5-fluorouracil with leucovorin, irinotecan, and oxaliplatin) is currently the standard of care for patients with resectable pancreatic cancer. The main concern regarding adjuvant chemotherapy is that only half of patients actually receive adjuvant treatment. Neoadjuvant chemotherapy, on the other hand, guarantees early systemic treatment and may increase chemotherapy use and thereby improve overall survival. Furthermore, it may prevent futile surgery in patients with rapidly progressive disease. However, some argue that neoadjuvant therapy delays surgery, which could lead to progression towards unresectable disease and thus offset the potential benefits. Comparison of perioperative (i.e., neoadjuvant and adjuvant) with (only) adjuvant administration of mFOLFIRINOX in a randomized controlled trial (RCT) is needed to determine the optimal approach. METHODS: This multicenter, phase 3, RCT will include 378 patients with resectable pancreatic ductal adenocarcinoma with a WHO performance status of 0 or 1. Patients are recruited from 20 Dutch centers and three centers in Norway and Sweden. Resectable pancreatic cancer is defined as no arterial contact and ≤ 90 degrees venous contact. Patients in the intervention arm are scheduled for 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (2-week cycle of oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, irinotecan 150 mg/m2 at day 1, followed by 46 h continuous infusion of 5-fluorouracil 2400 g/m2). Patients in the comparator arm start with surgery followed by 12 cycles of adjuvant mFOLFIRINOX. The primary outcome is overall survival by intention-to-treat. Secondary outcomes include progression-free survival, resection rate, quality of life, adverse events, and surgical complications. To detect a hazard ratio of 0.70 with 80% power, 252 events are needed. The number of events is expected to be reached after the inclusion of
- Published
- 2023
4. Microarray profile of the humoral immune response to influenza vaccination in breast cancer patients treated with chemotherapy.
- Author
-
Wumkes ML, van der Velden AM, de Bruin E, Meerveld-Eggink A, Koopmans MP, Rimmelzwaan GF, Rijkers GT, and Biesma DH
- Subjects
- Adult, Aged, Cyclophosphamide therapeutic use, Epirubicin therapeutic use, Female, Fluorouracil therapeutic use, Hemagglutination Inhibition Tests, Humans, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines administration & dosage, Influenza Vaccines adverse effects, Influenza, Human prevention & control, Middle Aged, Protein Array Analysis, Vaccination, Antibodies, Viral blood, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms immunology, Immunity, Humoral, Influenza A virus immunology, Influenza Vaccines immunology
- Abstract
Background: Patients treated with chemotherapy have an impaired response to influenza virus vaccination compared to healthy controls. Little is known about the broadness of the antibody response in these patients., Methods: Breast cancer patients on FEC (5-fluorouracil, epirubicin and cyclophosphamide) chemotherapy regimens were vaccinated with influenza virus vaccine. Sera were obtained before and three weeks after vaccination. In addition to the determination of virus-specific antibody titres by hemagglutination inhibition assay, the broadness of the response was assessed by the use of a protein microarray and baseline titres were compared with an age-matched reference group., Results: We included 38 breast cancer patients and found a wide variety in serum antibody response after vaccination. Patients with a history of influenza vaccination had higher pre-vaccination titres, which were comparable to the reference group. Increasing number of cycles of chemotherapy did not have a negative effect on influenza array antibody levels, nor on the HI antibody response., Conclusions: Overall there was a broad serum antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast cancer., (Copyright © 2017. Published by Elsevier Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
5. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours.
- Author
-
Wumkes ML, van der Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, van der Velden AW, Westerman M, Meerveld-Eggink A, Rimmelzwaan GF, Rijkers GT, and Biesma DH
- Subjects
- Adult, Aged, Breast Neoplasms immunology, Colorectal Neoplasms immunology, Female, Humans, Influenza Vaccines administration & dosage, Influenza, Human immunology, Male, Middle Aged, Netherlands, Serum immunology, Antibodies, Viral blood, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Colorectal Neoplasms drug therapy, Influenza Vaccines immunology, Influenza, Human prevention & control, Vaccination methods
- Abstract
Background: Higher rates of hospitalization and mortality are described in oncology patients with influenza virus infection compared to the general population. Yearly influenza vaccination is recommended for patients treated with chemotherapy. The optimal moment to administer the vaccine during a treatment cycle has not been studied extensively., Patients and Methods: During the influenza season 2011-2012 we conducted a multicenter randomized controlled trial (OFLUVAC, NTR2858, no sponsoring) in the Netherlands. Patients receiving adjuvant chemotherapy for breast or colorectal cancer were randomized between early (day 5 after chemotherapy) and late (day 16 after chemotherapy) vaccination with the influenza virus vaccine (Influvac(®) 2011/2012-Vaxigrip(®) 2011/2012). Influenza virus-specific antibody titres were determined before, 3 and 12 weeks after vaccination by haemagglutination inhibition., Results: Thirty-eight breast cancer patients (early=21; late=17) and 18 colorectal cancer patients (early=8; late=10) were analyzed. In breast cancer patients overall serologic responses were adequate. A statistically significant higher response in patients who received early compared to late vaccination in the chemotherapy cycle was observed. Geometric mean titres post vaccination on day 5 versus day 16 were 69.3 versus 27.4 (H3N2), 76.4 versus 17.5 (H1N1) and 34.4 versus 26.0 (B/Brisbane), respectively. In colorectal cancer patients overall serologic responses were adequate, no significant difference was found between early and late vaccination. Geometric mean titres post vaccination on day 5 versus day 16 were 170.1 versus 192.4 (H3N2), 233.0 versus 280.8 (H1N1) and 62.6 versus 75.9 (B/Brisbane), respectively., Conclusion: Overall antibody response to the influenza virus vaccine in patients treated with chemotherapy for breast or colorectal cancer patients is adequate. Breast cancer patients seem to mount the best antibody response when vaccinated early after a chemotherapy cycle (≤day 5). No difference was found between early and late vaccination in colorectal cancer patients., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
6. Influenza vaccination coverage in patients treated with chemotherapy: current clinical practice.
- Author
-
Wumkes ML, van der Velden AM, van der Velden AW, Stouthard JM, Nijziel MR, Westerman M, Beeker A, Meerveld-Eggink A, Rijkers GT, and Biesma DH
- Subjects
- Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Colorectal Neoplasms drug therapy, Female, General Practitioners psychology, General Practitioners statistics & numerical data, Health Knowledge, Attitudes, Practice, Humans, Influenza Vaccines immunology, Influenza, Human immunology, Male, Middle Aged, Netherlands, Surveys and Questionnaires, Breast Neoplasms immunology, Colorectal Neoplasms immunology, Influenza Vaccines administration & dosage, Influenza, Human prevention & control, Practice Patterns, Physicians' statistics & numerical data
- Abstract
Background: Influenza virus vaccination is recommended for patients treated with chemotherapy. Little is known about vaccination coverage in these patients., Methods: Vaccination coverage in the Netherlands was analysed by questionnaires completed by general practitioners, within a catchment area of 1.3 million people, in the period 2010-2011., Results: Of 433 eligible adult patients treated with chemotherapy for breast or colorectal cancer, 144 patients gave permission for us to approach their general practitioner with a questionnaire. General practitioners were asked about vaccination coverage, awareness of recommendations and their opinion about the responsibility for vaccination. We received 114 (79%) completed questionnaires. Sixty-seven out of 114 patients (59%) were vaccinated against influenza. Forty-four (66%) of these patients also had an indication for vaccination based on age (age ≥60 years). According to 48% of the general practitioners, the responsibility for vaccination belongs to the competence of the treating medical oncologist., Conclusion: Influenza vaccination coverage is limited to 59% of patients treated with chemotherapy. Guidelines for responsibility (general practitioner or medical oncologist) may increase the vaccination rate of cancer patients.
- Published
- 2013
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.